IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Update

IceCure Medical Ltd. (NASDAQ:ICCM) was the recipient of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 89,416 shares, a decrease of 87.6% from the May 31st total of 718,392 shares. Currently, 3.3% of the shares of the company are sold short. Based on an average trading volume of 160,692 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ICCM. Alliance Global Partners assumed coverage on IceCure Medical in a report on Monday, May 4th. They set a “buy” rating on the stock. Maxim Group cut their price objective on IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, IceCure Medical has an average rating of “Hold” and a consensus target price of $62.70.

IceCure Medical Price Performance

Shares of ICCM stock traded down $1.29 during trading on Friday, reaching $5.73. The company had a trading volume of 536,508 shares, compared to its average volume of 1,673,341. IceCure Medical has a one year low of $2.12 and a one year high of $42.00. The company has a market capitalization of $16.09 million, a PE ratio of -0.80 and a beta of 0.40. The firm’s 50 day simple moving average is $6.77 and its two-hundred day simple moving average is $13.83.

IceCure Medical (NASDAQ:ICCM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.03). IceCure Medical had a negative net margin of 441.60% and a negative return on equity of 211.73%. The business had revenue of $0.91 million for the quarter, compared to the consensus estimate of $1.34 million. Analysts forecast that IceCure Medical will post -3.51 earnings per share for the current year.

Key Headlines Impacting IceCure Medical

Here are the key news stories impacting IceCure Medical this week:

• Positive Sentiment: IceCure Medical said it has regained compliance with Nasdaq’s minimum bid price requirement, removing a delisting-related overhang that had been hanging over the shares. IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
• Positive Sentiment: Brookline Capital Markets raised near-term earnings estimates for several periods, including Q2, Q3, Q4, FY2026, FY2027, and FY2028, signaling a somewhat better earnings outlook than before. Icecure Medical Earnings Estimates, EPS & Revenue | NASDAQ:ICCM
• Neutral Sentiment: Short interest fell sharply in June to 89,416 shares, which may reduce bearish pressure, but the company remains a thinly traded microcap and sentiment can still swing quickly.
• Negative Sentiment: Analysts still expect IceCure to lose money in the coming years, and the company has a history of missing earnings and revenue estimates, keeping fundamental concerns in focus.

Hedge Funds Weigh In On IceCure Medical

Large investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in shares of IceCure Medical during the 4th quarter worth about $67,000. Concurrent Investment Advisors LLC acquired a new stake in shares of IceCure Medical in the fourth quarter valued at approximately $48,000. Finally, Virtu Financial LLC bought a new stake in IceCure Medical during the fourth quarter worth about $39,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.